Curewell Capital Acquires Majority Stake in Wilmington PharmaTech

Wilmington PharmaTech (WPT), a manufacturer of small molecule active pharmaceutical ingredients (API) based in the United States, has announced a significant investment by Los Angeles-based private equity firm Curewell Capital. This deal grants Curewell a majority stake in the company, aiming to accelerate WPT’s growth and bolster domestic pharmaceutical manufacturing capabilities.

The partnership will provide crucial growth capital intended to expand Wilmington PharmaTech’s manufacturing footprint. As part of the agreement, Hui-Yin “Harry” Li, Ph.D., the founder and CEO of WPT, will maintain a substantial ownership stake and continue to lead the organization alongside its existing management team.

Expansion Plans and Market Demand

Founded in 2003, Wilmington PharmaTech has established itself as a trusted partner for global drug developers, providing integrated services that encompass discovery, clinical development, and commercial-scale manufacturing. The company operates from its 54-acre campus in Delaware, which features two state-of-the-art facilities equipped with current Good Manufacturing Practice (cGMP) and high potency API suites. Additionally, WPT has an R&D center located in Suzhou, China.

Dr. Li expressed optimism regarding the investment, stating, “Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies. We are committed to expanding our capabilities and capacity to better serve our global biopharmaceutical partners.”

In light of increasing demand for specialized pharmaceutical manufacturing within the United States, Michael Dal Bello, a partner at Curewell Capital, emphasized the significance of the investment. He noted that it will enable Wilmington PharmaTech to enhance its operational capacity in response to the growing market need for reliable, high-quality manufacturing solutions.

Strategic Positioning in the Industry

The transaction strategically positions Wilmington PharmaTech to capitalize on both domestic and international demand for advanced API development. It aims to solidify the company’s role as a key manufacturing partner for biopharmaceutical innovators in the U.S. industry.

Curewell Capital’s investment arrives at a pivotal moment, as the pharmaceutical sector increasingly seeks dependable manufacturing partners to navigate the complexities of drug development and production. As Wilmington PharmaTech embarks on this new chapter, the collaboration is expected to drive innovation and growth in the rapidly evolving pharmaceutical landscape.

As the company moves forward, stakeholders and industry observers will be keen to see how this partnership unfolds, particularly in an environment marked by increasing demand for specialized pharmaceutical services.